Clinical

Dataset Information

0

Phase II study of TAS-102 plus bevacizumab as maintenance therapy after induction chemotherapy with bevacizumab, oxaliplatin, and fluoropyrimidine in patients with metastatic colorectal cancer


ABSTRACT: Interventions: TAS-102 plus Bevacizumab TAS-102 35 mg/time, twice a day, oral intake Day1-5,8-12 Bevacizumab venous injection, 5.0 mg/kg Day1,15 Patients will continue study treatment until disease progression Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2646473 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2024-08-26 | GSE275628 | GEO
| 2612965 | ecrin-mdr-crc
2020-10-15 | GSE139050 | GEO
| 2635113 | ecrin-mdr-crc
| 2206138 | ecrin-mdr-crc
2013-07-01 | E-GEOD-45161 | biostudies-arrayexpress
2019-02-07 | GSE126168 | GEO
| PRJNA1152270 | ENA
| 2637963 | ecrin-mdr-crc
| PRJNA578152 | ENA